<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04456842</url>
  </required_header>
  <id_info>
    <org_study_id>001/2018</org_study_id>
    <nct_id>NCT04456842</nct_id>
  </id_info>
  <brief_title>Cardiovascular Registry of Atrial Fibrillation</brief_title>
  <acronym>LACROSS</acronym>
  <official_title>Cardiovascular Registry of Atrial Fibrillation in Latin America: The LACROSS Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brazilian Clinical Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brazilian Clinical Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Follow a representative sample of Latin American patients diagnosed with atrial fibrillation&#xD;
      to set data on demographic characteristics, documenting antithrombotic therapy, describe the&#xD;
      INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke,&#xD;
      hemorrhage and death&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be followed 6 months and 1 year after the baseline visit and will be collected&#xD;
      data of antithrombotic therapy, laboratory data, discontinuation rates of antithrombotic&#xD;
      therapy and clinical outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 4, 2020</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>INR control rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Oral anticoagulation discontinuation rate</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of death</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of stroke</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of systemic embolism</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of major bleeding</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of electrical cardioversion</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of percutaneous ablation of AF</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of atrioventricular junction ablation</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of patients that need of pacemaker implantation</measure>
    <time_frame>12 monts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of other cardiovascular hospitalization</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">3000</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Atrial Flutter</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patient Registry Data</intervention_name>
    <description>To set data on demographic characteristics,documenting antithrombotic therapy, describe the INR control level of VKA users, discontinuation rates and clinical outcomes, such as stroke, hemorrhage and death.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with Atrial Fibrilation or Atrial Flutter&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years-old that signed informed consent;&#xD;
&#xD;
          -  Atrial Fibrillation or Atrial Flutter at the time of inclusion documented in source&#xD;
             document;&#xD;
&#xD;
          -  If the patient is not in atrial fibrillation or Atrial Flutter rhythm, s/he should&#xD;
             have 2 electrographic records, at least 15 days apart between them, with one of them&#xD;
             being performed within the last 6 months before enrollment (AF may be documented by&#xD;
             12-lead ECG, Holter monitor-24h);&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who did not agree to participate.&#xD;
&#xD;
          -  Patients without possibility of monitoring for one year.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renato D. Lopes, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Instituto Brasileiro de Pesquisa Thomaz de Carvalho - BCRI</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renato D. Lopes, MD, PhD</last_name>
    <phone>55 11 5904 7339</phone>
    <email>renato.lopes@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Prevención Cardiovascular Salta</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Cuneo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Servicios Médicos El Castaño</name>
      <address>
        <city>San Juan</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Moira Alvarez, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Cardiovascular San Luis</name>
      <address>
        <city>San Luis</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan Albisu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Clinicas del Litoral SRL</name>
      <address>
        <city>Santa Fe</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miguel Hominal, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Alvorada Taguatinga Ltda</name>
      <address>
        <city>São Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pedro Gabriel Melo de Barros e Silva, MD, PhD</last_name>
      <email>drpedrobarros80@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundacion Valle del Lili</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luis Fernando Pava</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 23, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrilation</keyword>
  <keyword>Antithrombotic therapy</keyword>
  <keyword>Atrial Flutter</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Atrial Flutter</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

